Data protection Impressum

Personalized Medicine

SOPHiA GENETICS, the Lausanne-based leader in AI-driven precision medicine, has closed an oversubscribed public offering with gross proceeds of USD 57.5 million to expand its platform, applications and partnerships.

SOPHiA GENETICS raises USD 57.5 million in oversubscribed public offering

22 June 2026

CSEM and MOMM Diagnostics have developed a point-of-care preeclampsia test up to 100 times more sensitive than conventional lateral flow assays.

CSEM and MOMM Diagnostics develop rapid preeclampsia test

26 May 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2026)

29 April 2026

ONWARD Medical has secured EUR 40.6 million through an accelerated bookbuild offering led by a EUR 25 million investment from EQT Life Sciences, extending the company's cash runway into the first quarter of 2028.

ONWARD Medical raises EUR 40 million to extend ARC therapy commercialization

20 April 2026

Geneva-based dEEGtal has appointed neurotechnology entrepreneur and investor Ann Bunnenberg to its board of directors, as the AI-powered brain signal platform advances clinical studies across Switzerland, Spain, and the United States ahead of a CHF 4–5 million seed round.

dEEGtal strengthens governance and advances clinical validation across three continents

14 April 2026

HeroSupport, a spin-off from the University Hospitals of Geneva, has obtained CE Mark certification for VENUS SHELL, a personalized 3D-printed breast immobilization system for prone radiotherapy.

HeroSupport receives CE Mark for its VENUS SHELL radiotherapy device

10 March 2026

Alithea Genomics has completed its seed financing round with an additional CHF 3 million, bringing the total to CHF 6.9 million, to accelerate the commercialization of its large-scale RNA sequencing platforms for drug screening and toxicology.

Alithea Genomics raises CHF 6.9 million to industrialize RNA sequencing

9 March 2026

HemostOD has been awarded a CHF 2 million Innosuisse grant to support the preclinical development of its donor-free, off-the-shelf human blood platelets for transfusion.

HemostOD secures CHF 2 million to advance donor-free platelet development

9 February 2026

Researchers from the Francis Crick Institute and Bern-based AlveoliX have developed the first human lung-on-chip model built entirely from genetically identical cells, opening new perspectives for personalised respiratory disease research.

AlveoliX contributes to first lung-on-chip model using genetically identical human cells

19 January 2026

Geneva-based biotech start-up FluoSphera has raised CHF 1.15 million to expand its human-relevant preclinical testing platform, supporting the shift toward more predictive and non-animal drug development models.

FluoSphera raises CHF 1.15 million to scale human-based preclinical drug testing

19 January 2026

1 2 3 4 5 … 12